LEADER 04909nam 2200553 a 450 001 9910141646903321 005 20230803025526.0 010 $a3-527-67042-4 010 $a1-299-24148-4 010 $a3-527-67043-2 035 $a(CKB)2670000000337921 035 $a(EBL)1129769 035 $a(OCoLC)829460534 035 $a(MiAaPQ)EBC1129769 035 $a(Au-PeEL)EBL1129769 035 $a(CaPaEBR)ebr10662568 035 $a(CaONFJC)MIL455398 035 $a(EXLCZ)992670000000337921 100 $a20130306d2013 uy 0 101 0 $aeng 135 $aurcn||||||||| 200 00$aMinicircle and miniplasmid DNA vectors$b[electronic resource] $ethe future of nonviral and viral gene transfer /$fedited by Martin Schleef 210 $aWeinheim, Germany $cWiley-Blackwell$d2013 215 $a1 online resource (259 p.) 300 $aDescription based upon print version of record. 311 $a3-527-32456-9 320 $aIncludes bibliographical references and index. 327 $aMinicircle and Miniplasmid DNA Vectors: The Future of Non-Viral and Viral Gene Transfer; Contents; List of Contributors; Preface; 1 Minicircle Patents: A Short IP Overview of Optimizing Nonviral DNA Vectors; 2 Operator-Repressor Titration: Stable Plasmid Maintenance without Selectable Marker Genes; 2.1 Introduction; 2.2 Antibiotics and Metabolic Burden; 2.3 The Mechanism of ORT; 2.4 ORT Strain Development; 2.5 ORT Miniplasmids; 2.6 DNA Vaccine and Gene Therapy Vectors; 2.7 ORT-VAC: Plasmid-Based Vaccine Delivery Using Salmonella enterica; 2.8 Recombinant Protein Expression 327 $a2.9 Conclusions and Future DevelopmentsReferences; 3 Selection by RNA-RNA Interaction: Maximally Minimized Antibiotic Resistance-Free Plasmids; 3.1 Gene Therapy and DNA Vaccines: Emerging Technologies; 3.1.1 Therapeutic Plasmids: General Design Principles; 3.2 Therapeutic Plasmids: Novel Design and the Problem of Selection; 3.2.1 Replication Control of ColE1-Type Plasmids as an Alternative Selection Marker; 3.2.2 The MINIback Concept: Selection by RNA-RNA Interaction; 3.2.3 Improved Production Processes by MINIback Plasmids; 3.2.4 Improving Sequence Composition; 3.2.5 Efficient Gene Transfer 327 $a3.3 Conclusions Acknowledgments; References; 4 Plasmid-Based Medicinal Products - Focus on pFAR: A Miniplasmid Free of Antibiotic Resistance Markers; 4.1 Introduction: Rationale for the Development of Biosafe DNA Plasmid Vectors; 4.2 Specific Requirements for the Use of DNA Product as Medicines; 4.2.1 Requirements for Plasmid Quality and Purity; 4.2.2 Requirements for the Removal of Antibiotic Resistance Markers from Plasmid DNA; 4.2.2.1 Requirements for Biosafe Plasmids; 4.2.2.2 Positive Impact on the Removal of Antibiotic Resistance Markers 327 $a4.2.2.3 Effect of Plasmid Size on Gene Transfer Efficiency In Vitro and In Vivo 4.3 Nonviral Gene Vectors Devoid of Antibiotic Resistance Markers; 4.3.1 Generalities; 4.3.2 Selection Systems Devoid of Antibiotic Resistance Markers; 4.3.2.1 Complementation of Host Auxotrophy by a Function-Encoded Plasmid; 4.3.2.2 The Operator-Repressor Titration (ORT) System; 4.3.2.3 Protein-Based Antidote/Poison Selection Systems; 4.3.2.4 RNA-Based Selection Marker; 4.3.2.5 Suppression of a Nonsense Mutation; 4.4 The pFAR Plasmid Family; 4.4.1 Description of the Antibiotic-Free Selection System 327 $a4.4.2 pFAR Vectors Promote Efficient Expression in Several Types of Mammalian Cells 4.4.2.1 In Vitro Transfection Study; 4.4.2.2 In Vivo Transfection Studies; 4.4.3 Concluding Remarks on the pFAR4 Biosafe Miniplasmid; 4.5 Concluding Remarks and Perspectives; Acknowledgments; References; 5 Plasmid DNA Concatemers: Influence of Plasmid Structure on Transfection Efficiency; 5.1 Introduction; 5.2 Plasmid DNA Topology and Size; 5.3 Plasmid DNA Concatemers; 5.4 Conclusions; Acknowledgments; References; 6 Analytical Tools in Minicircle Production; 6.1 Introduction 327 $a6.1.1 Gene Transfer for Therapy, Vaccination, and Stem Cells 330 $aThis first title on the topic provides complete coverage, including the molecular basis, production and possible biomedical applications. Written by the most prominent academic researchers in the field as well as by researchers at one of the world's leading companies in industrial production of minicircle DNA, this practical book is aimed at everyone who is directly or indirectly involved in the development of gene therapies. 606 $aGene therapy 606 $aGenetic vectors 606 $aPlasmids 615 0$aGene therapy. 615 0$aGenetic vectors. 615 0$aPlasmids. 676 $a615.895 701 $aSchleef$b M$g(Martin)$0872773 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910141646903321 996 $aMinicircle and miniplasmid DNA vectors$91948453 997 $aUNINA